Unity Biotechnology to focus on senolytic programs in ophthalmology, neurology
Unity Biotechnology will restructure to focus on ophthalmology and neurology pursuits, according to a press release.
“Unity is a pioneer in the development of therapeutics targeting senescent cells at the crux of many age-related diseases, and we will continue to build on this scientific foundation as we advance our pipeline,” Anirvan Ghosh, PhD, CEO of Unity, said in the release.
A phase 1 study of UBX1325 in diabetic macular edema is expected to begin this year. The treatment targets Bcl-xL, a mechanism to eliminate senescent cells in age-related eye diseases.
“We are excited about advancing Unity’s lead ophthalmology program, UBX1325, into clinical studies in patients with diabetic macular edema, an indication with a well-defined development path and objective endpoints,” Ghosh said.
The company plans to reduce its employee base by 30% to about 75 full-time employees, which will help extend the cash runway through mid-2022.
Read more about